Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 10.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,473 shares of the biopharmaceutical company’s stock after selling 8,297 shares during the quarter. Ensign Peak Advisors Inc owned approximately 0.06% of Alnylam Pharmaceuticals worth $17,854,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Capital International Investors grew its holdings in Alnylam Pharmaceuticals by 15.8% during the 4th quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company’s stock valued at $686,641,000 after buying an additional 488,814 shares during the last quarter. Vanguard Group Inc. increased its position in Alnylam Pharmaceuticals by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after purchasing an additional 287,064 shares in the last quarter. Capital Research Global Investors increased its position in Alnylam Pharmaceuticals by 7.3% during the 1st quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock worth $470,018,000 after purchasing an additional 214,908 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in Alnylam Pharmaceuticals by 5.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock valued at $550,837,000 after purchasing an additional 201,784 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new position in Alnylam Pharmaceuticals in the 1st quarter valued at about $18,886,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ALNY has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, August 30th. Bank of America increased their price target on Alnylam Pharmaceuticals from $295.00 to $307.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Barclays lifted their price objective on Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Morgan Stanley upped their target price on Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the company an “equal weight” rating in a research note on Friday, July 12th. Finally, Stifel Nicolaus raised their price target on Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. Seven research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $279.14.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 7,093 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $261.00, for a total value of $1,851,273.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at approximately $19,168,101. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the sale, the director now directly owns 136 shares in the company, valued at $35,632. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 7,093 shares of the business’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $261.00, for a total transaction of $1,851,273.00. Following the transaction, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at approximately $19,168,101. The disclosure for this sale can be found here. In the last quarter, insiders sold 57,491 shares of company stock worth $15,446,733. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $271.83 on Tuesday. The firm has a fifty day moving average of $260.43 and a two-hundred day moving average of $200.28. The firm has a market cap of $34.38 billion, a P/E ratio of -101.43 and a beta of 0.38. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The firm had revenue of $659.83 million during the quarter, compared to analyst estimates of $447.22 million. During the same quarter last year, the business posted ($2.21) earnings per share. The firm’s revenue for the quarter was up 107.0% on a year-over-year basis. On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.